BFC Planning’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$620 Hold
30
– – ﹤0.01% 3259
2026
Q2
$772 Hold
30
– – ﹤0.01% 3197
2026
Q1
$576 Hold
30
– – ﹤0.01% 2836
2025
Q4
$495 Hold
30
– – ﹤0.01% 2931
2025
Q3
$436 Hold
30
– – ﹤0.01% 2770
2025
Q2
$420 Sell
30
-29
-49% -$408 ﹤0.01% 2564
2025
Q1
$802 Hold
59
– – ﹤0.01% 2474
2024
Q4
$1.2K Sell
59
-17
-22% -$435 ﹤0.01% 2378
2024
Q3
$2.21K Buy
+76
New +$1.88K ﹤0.01% 2259

Other funds holding DNLI

BFC Planning's DNLI Position: Q3 2026 in Review

BFC Planning held its Denali Therapeutics (DNLI) position steady in Q3 2026 at 30 shares worth $620. The position accounts for ﹤0.01% of the portfolio, ranked #3259.

BFC Planning first reported a position in DNLI in Q3 2024 and has held it in 9 quarters since. The position peaked at $2.21K in Q3 2024. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • BFC Planning held 30 shares of Denali Therapeutics worth $620 as of Q3 2026.
  • BFC Planning left its Denali Therapeutics share count unchanged in Q3 2026.
  • Denali Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3259 holding.
  • BFC Planning first reported a position in Denali Therapeutics in Q3 2024 and has held it in 9 quarters since.
  • BFC Planning's Denali Therapeutics position peaked at $2.21K in Q3 2024.
  • 217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.